Thompson Davis & Co’s ResMed RMD Stock Holding History

Thompson Davis & Co’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-338	Closed	-$20K	–	1151
2016 Q1	$20K	Buy	+338	New	+$19.1K	0.03%	467
2015 Q3	–	Sell	-20	Closed	-$1K	–	1226
2015 Q2	$1K	Sell	20 -140	-88%	-$8.84K	﹤0.01%	1160
2015 Q1	$11K	Buy	+160	New	+$10.4K	0.01%	701

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CBOA

Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Thompson Davis & Co's RMD Position: Q2 2016 in Review

Thompson Davis & Co sold out of ResMed (RMD) in Q2 2016, closing a stake of 338 shares — an estimated $20K sold.

Thompson Davis & Co first reported a position in RMD in Q1 2015 and held it in 3 quarters. The position peaked at $20K in Q1 2016. 361 funds tracked by Wall St. Rank hold RMD as of Q2 2016.

Thompson Davis & Co reported no remaining ResMed position as of Q2 2016 after selling out during the quarter.
Thompson Davis & Co sold 338 ResMed shares in Q2 2016, an estimated $20K.
Thompson Davis & Co first reported a position in ResMed in Q1 2015 and held it in 3 quarters.
Thompson Davis & Co's ResMed position peaked at $20K in Q1 2016.
361 funds tracked by Wall St. Rank held ResMed as of Q2 2016.

Based on Thompson Davis & Co's 13F filing for Q2 2016, filed 9 Aug 2016.